Trials / Not Yet Recruiting
Not Yet RecruitingNCT06557304
The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
This is a Multicenter, Retrospective Real-world Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Multicenter, Retrospective Real-world Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BTK inhibitor | patients with treatment naive or R/R CLL who treatment with BTK inhibitor |
Timeline
- Start date
- 2024-09-01
- Primary completion
- 2026-09-01
- Completion
- 2027-12-30
- First posted
- 2024-08-16
- Last updated
- 2024-08-21
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06557304. Inclusion in this directory is not an endorsement.